Spots Global Cancer Trial Database for PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis
Official Title: A Phase Ib Trial of Intraperitoneal Cisplatin and Nab-paclitaxel Administered by Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Advanced Malignancies Confined to the Peritoneal Cavity
Study ID: NCT04000906
Conditions
Study Description
Brief Summary: Phase Ib trial including investigating the combination of nab-paclitaxel and cisplatin in patients diagnosed with peritoneal carcinomatosis related to pancreatic, oeso-gastric, ovarian cancer or primitive peritoneal mesothelioma.
Detailed Description: Phase Ib trial investigating the combination of intraperitoneal Cisplatin (10.5 mg/m2) and Nab-paclitaxel (escalated dose from 7.5 mg/m2 to 70 mg/m2) administered by pressurized intraperitoneal aerosol chemotherapy (PIPAC) every 4-6 weeks for 3 cycles.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Hospital, Lausanne, Lausanne, Vaud, Switzerland
University Hospital, Geneva, Geneva, , Switzerland
Contact Details
Name: Intidhar Labidi-Galy, MD, PhD
Affiliation: University Hospital, Geneva
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
